Expressions of TRAIL and Its Receptors in Rectal Cancer Tissue_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HU Jiankun ¹ , YANG Kun ¹ , LI Chunmei ² , ZHOU Zongguang ³ , ZHANG Bo ¹ , YU Yongyang ³ , CHEN Xinzu ¹ , LI Li ³ , CHEN Zhixin ¹ , CHEN Jiaping. ¹

1.Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;;
2.Department of Gynecology and Obstetrics, West China The Second Hospital, Sichuan University, Chengdu 610041, China;;
3.Department of Anal-Colorectal Surgery, West China Hospital, Sichuan University, Chengdu 610041, ChinaCorresponding Author: HU Jian-kun， E-mail: hujkwch@126.com;

Corresponding author：

Keywords：

Rectal cancer; Tumor necrosis factor related apoptosis inducing ligand; Immunohistochemistry

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expressions of tumor necrosis factor related apoptosis inducing ligand （TRAIL） and its receptors (DR4, DcR1) in human rectal cancer tissues and normal rectal tissues. MethodsThe expressions of TRAIL and its receptors (DR4, DcR1) in 31 cases of human rectal cancer tissues and 20 cases of normal rectal tissues were detected by immunohistochemical staining. ResultsThe positive expression rates of TRAIL, DR4 and DcR1 （32.26%， 29.03%， 0） were lower than those of normal rectal tissues （55.00%， 70.00%， 65.00%）, the difference was statistically significant(P=0.015， P=0.000， P=0.000). There were no relation between the expressions of TRAIL, DR4 and DcR1 and clinicopathologic characteristics (P gt;0.05). ConclusionThe expressions of TRAIL and its receptors (DR4, DcR1) in human rectal cancer tissues were lower than those of normal rectal tissues, which may suggest that the apoptotic effect induced by the interaction between TRAIL and its receptors has attenuated in human rectal cancer.

Citation： HU Jiankun,YANG Kun,LI Chunmei,ZHOU Zongguang,ZHANG Bo,YU Yongyang,CHEN Xinzu,LI Li,CHEN Zhixin,CHEN Jiaping.. Expressions of TRAIL and Its Receptors in Rectal Cancer Tissue. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(2): 137-140. doi: Copy

1.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[Ｊ]. CA Cancer J Clin, 2008; 58(2)： 71.
2.	Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[Ｊ]. J Clin Invest, 1999; 104(2)： 155.
3.	Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast[Ｊ]. Can J Surg, 1991; 34(4)： 349.
4.	Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[Ｊ]. Immunity, 1995; 3(6)： 673.
5.	Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors[Ｊ]. Science, 1997; 277(5327)： 818.
6.	Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[Ｊ]. J Biol Chem, 1998; 273(23)： 14363.
7.	Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms[Ｊ]. Curr Opin Immunol, 1998; 10(5)： 559.
8.	Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[Ｊ]. Nat Med, 1999; 5(2)： 157.
9.	Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract[Ｊ]. Oncogene, 1999; 18(28)： 4153.
10.	公伟，　刘军，梁飞，等.TRAIL受体在胰腺癌中的表达 [Ｊ]. 中国普外基础与临床杂志,2006;13(5)： 521.
11.	Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[Ｊ]. Immunity, 2000; 12(6)： 611.
12.	Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4[Ｊ]. Biochem Biophys Res Commun, 2000; 269(1)： 179.
13.	Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[Ｊ]. Science, 1997; 277(5327)： 815.
14.	Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors[Ｊ]. Cell Res, 2004; 14(5)： 359.
15.	陈心足，姜坤，胡建昆. TRAIL信号通路在胃癌的研究现状 [Ｊ]. 中国普外基础与临床杂志,2007;14(3)： 371.
16.	Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo[Ｊ]. Int J Gynecol Cancer, 2006; 16(2)： 538.
17.	公伟，李占元，曾庆东，等.肿瘤坏死因子相关凋亡诱导配体联合化疗药物杀伤胰腺癌细胞的研究 [Ｊ].中华肝胆外科杂志,2006;12(2)： 111.
18.	Itashiki Y，Harada K， Ferdous T,et al.Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice[Ｊ]. Anticancer Res, 2007; 27(4B)： 2365.
19.	Xu J, Zhou JY, Tainsky MA, et al. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2’-deoxycytidine sensitizes human breast cancer cells to adriamycin[Ｊ]. Cancer Res, 2007; 67(3)： 1203.
20.	Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma[Ｊ]. Gynecol Oncol, 2004; 92(3)： 794.
21.	Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[Ｊ]. Prostate, 2005; 62(2)： 165.
22.	Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[Ｊ]. Mol Cancer Ther, 2007; 6(4)： 1387.

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[Ｊ]. CA Cancer J Clin, 2008; 58(2)： 71.
2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[Ｊ]. J Clin Invest, 1999; 104(2)： 155.
3. Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast[Ｊ]. Can J Surg, 1991; 34(4)： 349.
4. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[Ｊ]. Immunity, 1995; 3(6)： 673.
5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors[Ｊ]. Science, 1997; 277(5327)： 818.
6. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[Ｊ]. J Biol Chem, 1998; 273(23)： 14363.
7. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms[Ｊ]. Curr Opin Immunol, 1998; 10(5)： 559.
8. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[Ｊ]. Nat Med, 1999; 5(2)： 157.
9. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract[Ｊ]. Oncogene, 1999; 18(28)： 4153.
10. 公伟，　刘军，梁飞，等.TRAIL受体在胰腺癌中的表达 [Ｊ]. 中国普外基础与临床杂志,2006;13(5)： 521.
11. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[Ｊ]. Immunity, 2000; 12(6)： 611.
12. Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4[Ｊ]. Biochem Biophys Res Commun, 2000; 269(1)： 179.
13. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[Ｊ]. Science, 1997; 277(5327)： 815.
14. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors[Ｊ]. Cell Res, 2004; 14(5)： 359.
15. 陈心足，姜坤，胡建昆. TRAIL信号通路在胃癌的研究现状 [Ｊ]. 中国普外基础与临床杂志,2007;14(3)： 371.
16. Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo[Ｊ]. Int J Gynecol Cancer, 2006; 16(2)： 538.
17. 公伟，李占元，曾庆东，等.肿瘤坏死因子相关凋亡诱导配体联合化疗药物杀伤胰腺癌细胞的研究 [Ｊ].中华肝胆外科杂志,2006;12(2)： 111.
18. Itashiki Y，Harada K， Ferdous T,et al.Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice[Ｊ]. Anticancer Res, 2007; 27(4B)： 2365.
19. Xu J, Zhou JY, Tainsky MA, et al. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2’-deoxycytidine sensitizes human breast cancer cells to adriamycin[Ｊ]. Cancer Res, 2007; 67(3)： 1203.
20. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma[Ｊ]. Gynecol Oncol, 2004; 92(3)： 794.
21. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[Ｊ]. Prostate, 2005; 62(2)： 165.
22. Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[Ｊ]. Mol Cancer Ther, 2007; 6(4)： 1387.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions of TRAIL and Its Receptors in Rectal Cancer Tissue

Abstract Full text Figures/Tables Video References Cited by

Format

Content